Publikationen in Zusammenarbeit mit Forschern von AstraZeneca (United Kingdom) (9)

2023

  1. Cluster Analyses From the Real-World NOVELTY Study: Six Clusters Across the Asthma-COPD Spectrum

    Journal of Allergy and Clinical Immunology: In Practice, Vol. 11, Núm. 9, pp. 2803-2811

2022

  1. Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications

    Diabetes Therapy, Vol. 13, Núm. 5, pp. 873-888

  2. The burden of mild asthma: Clinical burden and healthcare resource utilisation in the NOVELTY study

    Respiratory Medicine, Vol. 200

2018

  1. Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS

    Clinical and Translational Oncology, Vol. 20, Núm. 10, pp. 1261-1267

2017

  1. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial

    Arthritis and Rheumatology, Vol. 69, Núm. 9, pp. 1903-1913

2016

  1. 147P: Level of concordance between EGFR mutation status obtained from tissue/cytology and blood (plasma) for advanced non-small-cell lung cancer in Spain: ASSESS study

    Journal of Thoracic Oncology, Vol. 11, Núm. 4, pp. S122

  2. Computational Lexical Analysis of the Language Commonly Used to Describe Gout

    Arthritis Care and Research, Vol. 68, Núm. 6, pp. 763-768

2012

  1. Vandetanib with docetaxel as second-line treatment for advanced breast cancer: A double-blind, placebo-controlled, randomized Phase II study

    Investigational New Drugs, Vol. 30, Núm. 2, pp. 681-687

2003

  1. A comparison of primary care physicians and pneumologists in the management of asthma in Spain: ASES study

    Respiratory Medicine, Vol. 97, Núm. 8, pp. 872-881